Humoral SPARC/osteonectin protein in plasma cell dyscrasias

Annals of Hematology

Volumn 84, Issue 5, 2005, Pages 304-310

  Turk, Nikša ^a   Kusec, Rajko ^a   Jaksic, Branimir ^a   Turk, Zdenka ^a  

^a University of Zagreb   (Croatia)

Author keywords

Clinical significance; Matricellular protein SPARC osteonectin; Multiple myeloma; Plasma cell dyscrasias; Plasma level

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BETA 2 MICROGLOBULIN; IMMUNOGLOBULIN G; INTERLEUKIN 6; LACTATE DEHYDROGENASE; OSTEOCALCIN; OSTEONECTIN; TUMOR MARKER; PLASMA PROTEIN;

ADULT; AGED; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE ATROPHY; BONE MARROW BIOPSY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE COURSE; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGLOBULIN BLOOD LEVEL; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MULTIPLE MYELOMA; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; STATISTICAL SIGNIFICANCE; THROMBOCYTE COUNT; BLOOD; GENE EXPRESSION REGULATION; MIDDLE AGED; OSTEOLYSIS; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; BLOOD PROTEINS; BONE RESORPTION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OSTEOCALCIN; OSTEONECTIN; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 23244449686     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-004-0990-4     Document Type: Article

References (21)

1. Le Bail B, Faouzi S, Boussarie L, Guirouilh J, Blanc JF, Carles J, Bioulac-Sage P, Balabaud C, Rosenbaum J (1999) Osteonectin/SPARC is overexpressed in human hepatocellular carcinoma. J Pathol 189:46-52 10.1002/(SICI)1096-9896(199909)189:1<46::AID-PATH392>3.3.CO;2-O
2. Bataille R, Delmas PD, Chappard D, Sany J (1990) Abnormal serum bone Gla protein levels in multiple myeloma. Crucial role of bone formation and prognostic implications. Cancer 66:167-172
3. Bataille R, Harousseau JL (1997) Multiple myeloma. N Engl J Med 336:1657-1664 10.1056/NEJM199706053362307
4. Boccadoro M, Pileri A (1995) Plasma cell dyscrasias: Classification, clinical and laboratory characteristics, and differential diagnostics. In: Mandelli F (ed) Multiple myeloma. Baillieres Clin Haematol 8:705-720
5. Bornstein P, Sage H (2002) Matricellular proteins: Extracellular modulators of cell function. Curr Opin Cell Biol 14:608-616 10.1016/ S0955-0674(02)00361-7
6. Bradshow AD, Sage H (2001) SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest 107:1049-1054 1:CAS:528:DC%2BD3MXjsVCjtLw%3D
7. Brekken RA, Puolakkainen P, Graves DC, Workman G, Lubkin SR, Sage EH (2003) Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. J Clin Invest 111:487-495 10.1172/JCI200316804
8. Delany AM, Amling M, Priemel M, Howe C, Baron R, Canalis E (2000) Osteopenia and decreased bone formation in osteonectin-deficient mice. J Clin Invest 105:915-923
9. De S, Chen J, Narzhneva NV, Heston W, Brainard J, Sage EH, Byzova TV (2003) Molecular pathway for cancer metastasis to bone. J Biol Chem 278:39044-39050 10.1074/jbc.M304494200
10. De Vos J, Thykjaer T, Tarte K, Ensslen M, Raynaud P, Requirand G, Pellet F, Pantesco V, Reme T, Jourdan M, Rossi JF, Orntoft T, Klein B (2002) Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene 21:6848-6857 10.1038/ sj.onc.1205868
11. Durie BG, Salmon SE (1975) A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 36:842-854 1:STN:280:CSmD2c7kvFI%3D
12. Gilles C, Bassuk JA, Pulyaeva H, Sage H, Foidart JM, Thompson EW (1998) SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines. Cancer Res 58:5529-5536
13. Hedvat CV, Comenzo RL, Teruya-Feldstein J, Olshen AB, Ely SA, Osman K, Zhang Y, Kalakonda N, Nimer SD (2003) Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma. Br J Haematol 122:728-744 10.1046/ j.1365-2141.2003.04481.x
14. Jacob K, Webber M, Benayahu D, Kleinman HK (1999) Osteonectin promotes prostate cancer cell migration and invasion: A possible mechanism for metastasis to bone. Cancer Res 59:4453-4457
15. Ledda MF, Adris S, Bravo AI, Kairiyama C, Bover L, Chernajovsky Y, Mordoh J, Podhajcer OL (1997) Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. Nat Med 3:171-176 10.1038/nm0297-171
16. Porter PL, Sage EH, Lane TF, Funk SE, Gown AM (1995) Distribution of SPARC in normal and neoplastic human tissue. J Histochem Cytochem 43:791-800
17. Sakai N, Baba M, Nagasima Y, Kato Y, Hirai K, Kondo K, Kobayashi K, Yoshida M, Kaneko S, Kishida T, Kawakami S, Hosaka M, Inayama Y, Yao M (2001) SPARC expression in primary human renal cell carcinoma: upregulation of SPARC in sarcomatoid renal carcinoma. Hum Pathol 32:1064-1070 10.1053/hupa.2001.28244
18. Schiemann BJ, Neil JR, Schiemann WP (2003) SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-β-signaling system. Mol Biol Cell 14:3977-3988 10.1091/mbc.E03-01-0001
19. Serebruany VL, Atar D, Murugesan SR, Jerome S, Semaan H, Gurbel PA (2000) Effect of coronary thrombolysis on the plasma concentration of osteonectin (SPARC, BM40) in patients with acute myocardial infarction. J Thromb Thrombolysis 10:197-202 10.1023/A:1018774812613
20. Urba ska-Rys H, Wierzbowska A, Robak T (2003) Circulating angiogenic cytokines in multiple myeloma and related disorders. Eur Cytokine Netw 14:40-51
21. Yiu GK, Chan WY, Ng SW, Chan PS, Cheung KK, Berkowitz RS, Mok SC (2001) SPARC (secreted protein acidic and rich in cysteine) induces apoptosis in ovarian cancer cells. Am J Pathol 159:609-622